YARROW BIOSCIENCE, INC. (YARW) Operating Margin
- Operating margin · 12 months: Value -4134.65%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -4134.65% | Operating income / revenue. Period ending 2026-06-30. $-19.93M ÷ $482.00K × 100 ≈ -4134.65% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -19.93M USD | Operating Income (Loss) |
| Revenue | 482.00K USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
| Research and development | 9.84M USD | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-19.93M | $482.00K | (m) | $9.84M | (m) | -4134.65% |
| 2026-03-31 | $-24.37M | $454.00K | (m) | $13.93M | (m) | -5367.40% |
| 2025-12-31 | $-29.75M | $570.00K | (m) | $19.24M | (m) | -5219.12% |
| 2025-06-30 | $-42.60M | $476.00K | (m) | $30.94M | (m) | -8949.37% |
| 2025-03-31 | $-45.45M | $605.00K | (m) | $33.36M | (m) | -7513.06% |
| 2024-12-31 | $-43.64M | $501.00K | (m) | $30.95M | (m) | -8709.98% |
| 2024-09-30 | $-37.70M | $493.00K | (m) | $24.29M | (m) | -7646.86% |
| 2024-06-30 | $-30.84M | $486.00K | (m) | $17.35M | (m) | -6345.88% |
| 2024-03-31 | $-30.76M | $423.00K | (m) | $17.28M | (m) | -7272.58% |
| 2023-12-31 | $-29.26M | $424.00K | (m) | $16.31M | (m) | -6900.47% |
| 2023-09-30 | $-30.41M | $354.00K | (m) | $17.56M | $13.20M | -8590.40% |
| 2023-06-30 | $-33.51M | $407.00K | (m) | $19.79M | $14.13M | -8233.42% |
| 2023-03-31 | $-31.48M | $398.00K | (m) | $16.67M | $15.21M | -7909.30% |
| 2022-12-31 | $-34.30M | $477.00K | (m) | $18.39M | $16.39M | -7189.73% |
| 2022-09-30 | $-64.28M | $14.57M | (m) | $23.84M | $51.65M | -441.23% |
| 2022-06-30 | $-65.71M | $14.53M | (m) | $24.21M | $52.68M | -452.12% |
| 2022-03-31 | $-66.97M | $14.70M | (m) | $25.16M | $53.17M | -455.46% |
| 2021-12-31 | $-68.03M | $14.76M | $3.35M | $24.96M | $54.48M | -461.08% |
| 2021-09-30 | $-77.98M | $16.75M | $2.98M | $27.56M | $64.19M | -465.56% |
| 2021-06-30 | $-83.69M | $15.93M | $2.30M | $27.20M | $70.12M | -525.31% |
| 2021-03-31 | $-232.09M | $23.36M | $1.72M | $33.91M | $80.74M | -993.44% |
| 2020-12-31 | $-252.55M | $20.99M | $1.39M | $43.53M | $89.54M | -1203.00% |
| 2020-09-30 | $-248.36M | $16.40M | (m) | $53.60M | (m) | -1514.46% |
| 2020-06-30 | $-248.06M | $13.13M | (m) | $59.43M | (m) | -1889.30% |
| 2020-03-31 | $-100.25M | $1.44M | (m) | $58.87M | (m) | -6951.94% |
| 2019-12-31 | $-76.24M | $0.00 | (m) | $53.76M | (m) | (m) |
| 2019-09-30 | $-72.75M | $0.00 | (m) | $57.08M | (m) | (m) |
| 2019-06-30 | $-69.03M | $0.00 | (m) | $55.12M | (m) | (m) |
| 2019-03-31 | $-60.98M | (m) | (m) | $57.89M | (m) | (m) |
| 2018-12-31 | $-54.53M | $0.00 | (m) | $52.99M | (m) | (m) |
| 2018-09-30 | $-45.57M | (m) | (m) | $48.46M | (m) | (m) |
| 2018-06-30 | $-40.21M | (m) | (m) | $45.80M | (m) | (m) |
| 2018-03-31 | $-37.26M | (m) | (m) | $35.03M | (m) | (m) |
| 2017-12-31 | $-29.59M | (m) | (m) | $29.01M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-14.33M | (m) | (m) | $11.26M | (m) | (m) |
| 2015-12-31 | $-4.61M | (m) | (m) | $2.92M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |